Harbour BioMed Adds Veteran Immunology Executive to Scientific Advisory Board
Event summary
- Harbour BioMed appointed Dr. Dhavalkumar Patel as Scientific Advisor on June 11, 2026.
- Dr. Patel is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology.
- He previously led research at UCB and Novartis, contributing to the registration of multiple approved therapies.
- Dr. Patel's expertise spans immunology, oncology, and autoimmune disease areas.
The big picture
Harbour BioMed's appointment of Dr. Patel underscores its push to strengthen its immunology focus, leveraging his extensive experience in developing approved therapies. This move comes as the biopharmaceutical industry increasingly prioritizes targeted antibody therapeutics, particularly in high-unmet-need areas. Dr. Patel's dual background in academia and industry positions him to bridge translational research gaps, potentially accelerating Harbour BioMed's pipeline progress.
What we're watching
- Pipeline Acceleration
- How Dr. Patel's guidance will impact Harbour BioMed's immunology pipeline development.
- Strategic Partnerships
- Whether his industry connections will facilitate new collaborations or acquisitions.
- Regulatory Success
- The pace at which Harbour BioMed can advance its novel antibody candidates through clinical stages.
Related topics